Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

    Année de publication: 2023

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Commercial arrangement There is a managed access agreement, which includes a patient access scheme, for trastuzumab deruxtecan. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact commercialaccess@daiichi-sankyo.co.uk for details.